Shire Pharmaceuticals Extends Kidney-friendly Cooking Program
View PDF | Print View
by: Guest
Total views: 64
Word Count: 1724
PHILADELPHIA, April 10 /PRNewswire/ -- Shire Pharmaceuticals today announced plans to extend its Kidney Friendly Comfort Foods program by offering a new resource to chronic kidney disease (CKD) Stage 5 patients who also have diabetes. The Kidney Friendly Comfort Foods, Volume II: Eating Well for Chronic Kidney Disease Patients, Including Those With Diabetes cookbook, to be released in June 2007, will include dietary tips from renal dietitian Marianne Hutton and six new recipes from celebrity chef Katie Lee Joel.
Approximately 20 million Americans have some form of kidney disease and almost 500,000 have developed CKD Stage 5 and require dialysis. Many of these patients also have diabetes -- the leading cause of kidney failure in the United States. As more patients are trying to manage kidney disease along with diabetes, there is an increased need for resources that help patients and caregivers address the dietary modifications associated with both conditions.
"My dialysis patients are always struggling to manage their diets, which is even more challenging for those who also have diabetes and are subject to additional dietary modifications than those with CKD Stage 5 alone. I was delighted to have the opportunity to help develop the Kidney Friendly Comfort Foods, Volume II: Eating Well for Chronic Kidney Disease Patients, Including Those With Diabetes cookbook," said Marianne Hutton, R.D., C.D.E., program coordinator and instructor for the Northern California Center for Well-Being in Santa Rosa. "This cookbook is a valuable resource that can help patients take an active role in managing their conditions, while offering tasty, appropriate recipes the entire family can enjoy."
Shire partnered with Hutton and Katie Lee Joel, the first season host of Bravo's hit show, "Top Chef," for the 2007 Kidney Friendly Comfort Foods program. Together, they have worked to build on the success of the 2006 edition of the Kidney Friendly Comfort Foods: A Collection of Recipes for People With Chronic Kidney Disease cookbook, by creating a second edition focused on dialysis patients who also have diabetes. In an effort to provide these patients with healthy and creative meal options, the 2007 cookbook includes an upfront section that offers dietary tips for managing both CKD Stage 5 and diabetes, which was developed by Hutton. It also features 21 new, delicious and easy-to-make recipes, six of which were developed by Katie.
"I was excited to partner with Shire for a second year and share more of my recipes. I want patients to know that cooking kidney and diabetes friendly foods is not a sentence to boring food, and that this cookbook can help make meals more enjoyable for the entire family," said Katie.
Katie is familiar with the dietary modifications required for patients with kidney disease, as her grandfather was a dialysis patient. After her grandfather was diagnosed, the family was worried about his health, while he was more concerned about the restrictions it put on his diet. Katie and her grandmother began to research kidney disease diet restrictions and adapted many of her family's traditional recipes. The results were meals that the entire family could enjoy, while supporting her grandfather's dietary requirements. Katie's delicious Chicken Pot Pie is just one of many recipes that patients have to look forward to in the new cookbook.
"The Kidney Friendly Comfort Foods program is one of many resources Shire is offering the CKD Stage 5 community this year. We know patients often experience difficulties maintaining a low phosphorus diet, especially if they also have other diet restrictions as a result of their diabetes, and are eager to provide new resources to help patients manage their health," said Matt Handel, Shire, product general manager, FOSRENOL(R) U.S.
The Kidney Friendly Comfort Foods, Volume II: Eating Well for Chronic Kidney Disease Patients, Including Those With Diabetes cookbook will be available in June for free by visiting , or by calling 866-896-6152.
About Hyperphosphatemia It is important for people with CKD Stage 5 to follow a low phosphorus diet, because most dialysis patients will develop hyperphosphatemia (high serum phosphorus levels in the blood). Hyperphosphatemia can lead to serious long-term health problems for these patients, such as mineral deposits in the heart and blood vessels, bone disease and even death. Because phosphorus is found in so many foods, patients often cannot reach target blood phosphorus levels through dietary restriction and dialysis alone, and they generally treat hyperphosphatemia by taking phosphate binders at meals and snacks.
Hyperphosphatemia is a difficult condition to treat because it requires patients to follow a special diet and comply with a prescribed binder therapy regimen that may comprise up to nine pills a day. However, patients with hyperphosphatemia may be able to reduce their pill burden to as few as one tablet with each meal with treatments such as Shire's FOSRENOL(R). (Dosing based on three meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.)
About Katie Lee Joel Katie is currently writing her first cookbook, to be published next year by Simon and Schuster. The book is a compilation of updated classics from her archive of family recipes using the best seasonal ingredients. Katie regularly appears on Extra as a special correspondent, covering everything from red carpet events to food to fashion. Katie is a contributing editor to Gotham magazine, and her culinary and lifestyle column, Katie's Kitchen, is published weekly in its sister magazine Hamptons.
Katie was the first season host of Bravo's hit "Top Chef," a reality competition series for the culinary arts. In July 2005, Katie co-created the Web site with partner Aleishall Girard, a site dedicated to food and the importance of "conscious consumption." She resides in the New York area with her husband, musician Billy Joel.
FOSRENOL(R) FOSRENOL(R) is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD). FOSRENOL(R) is not indicated for the treatment of diabetes.
FOSRENOL(R) (lanthanum carbonate) is an effective, non-calcium, phosphate binder that reduces high phosphorus levels in ESRD patients. FOSRENOL(R) is formulated as an easy-to-use, unflavored, chewable-only tablet that can be taken without water, an important consideration for ESRD patients who must restrict their fluid intake.
FOSRENOL(R) is available in a broad range of dosage strengths, including the reformulated strengths of 500 mg, 750 mg and 1 g. With the reformulated doses, patients can achieve serum phosphorus target levels with as few as three tablets per day. (Dosing based on three meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.)
FOSRENOL(R) works by binding to dietary phosphorus in the gastrointestinal tract. Once bound, the FOSRENOL(R)/phosphorus complex cannot pass into the bloodstream and is eliminated from the body, thereby decreasing mean serum phosphorus levels.
FOSRENOL(R) has been clinically tested in more than 5,500 patients. Nearly 1,000 patients have been treated with lanthanum carbonate for more than one year. Over 64,000 patients have been treated with FOSRENOL(R). The long-term safety profile of FOSRENOL(R) shows no evidence of toxicity at clinical doses. Trials involving patients treated with FOSRENOL(R) showed sustained serum phosphorus reduction in a majority of patients.
Important Safety Information The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing. The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea). Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension. Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL(R) compared to alternative therapy for up to three years. The duration of treatment exposure and time of observation in the clinical program were too short to conclude that
FOSRENOL(R) does not affect the risk of fracture or mortality beyond three years. While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown. Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL(R) clinical studies. Caution should be used in patients with these conditions. FOSRENOL(R) should not be taken by patients who are nursing or pregnant. FOSRENOL(R) should not be taken by patients who are under 18 years of age.
For Full Prescribing Information on FOSRENOL(R), please visit .
SHIRE PLC Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: .
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD), SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's planned acquisition of New River Pharmaceuticals announced February 20, 2007; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2005.
Related: Shire Pharmaceuticals Extends Kidney-friendly Cooking Program
Additional information:
Shire Pharmaceuticals Extends Kidney-friendly Cooking Program: from www.pharmalive.com
Rating:
Not yet rated
Comments
No comments posted.
Add Comment
You do not have permission to comment. If you
log in, you may be able to comment.
